Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis

William V. Padula; Miguel Cordero-Coma; Taygan Yilmaz; Michéal J. Gallagher; Jonathan D. Campbell

doi:10.36469/9895

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:14028/feed

ISSN 2327-2236

Ophthalmology

Vol. 2, Issue 2, 2015

January 20, 2015 EDT

Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis

William V. Padula, Miguel Cordero-Coma, Taygan Yilmaz, William V. Padula, Michéal J. Gallagher, Jonathan D. Campbell,

autoimmune diseasebiologicuveitisophthalmologycost-minimization analysis

ccby-4.0

• https://doi.org/10.36469/9895

JHEOR

Padula WV, Cordero-Coma M, Yilmaz T, Padula WV, Gallagher MJ, Campbell JD. Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis. JHEOR. 2015;2(2):131-146. doi:10.36469/9895

View more stats